Development of therapeutics for treatment of Ebola virus infection

Haoyang Li; Tianlei Ying; Fei Yu; Lu Lu; Shibo Jiang

doi:10.1016/j.micinf.2014.11.012

Development of therapeutics for treatment of Ebola virus infection

Microbes Infect. 2015 Feb;17(2):109-17. doi: 10.1016/j.micinf.2014.11.012. Epub 2014 Dec 11.

Authors

Haoyang Li¹, Tianlei Ying¹, Fei Yu¹, Lu Lu², Shibo Jiang³

Affiliations

¹ Key Lab of Medical Molecular Virology of MOE/MOH, Shanghai Medical College, Fudan University, 130 Dong An Rd., Xuhui District, Shanghai 200032, China.
² Key Lab of Medical Molecular Virology of MOE/MOH, Shanghai Medical College, Fudan University, 130 Dong An Rd., Xuhui District, Shanghai 200032, China. Electronic address: lul@fudan.edu.cn.
³ Key Lab of Medical Molecular Virology of MOE/MOH, Shanghai Medical College, Fudan University, 130 Dong An Rd., Xuhui District, Shanghai 200032, China; Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10065, USA. Electronic address: shibojiang@fudan.edu.cn.

PMID: 25498866
DOI: 10.1016/j.micinf.2014.11.012

Abstract

Ebola virus infection can cause Ebola virus disease (EVD). Patients usually show severe symptoms, and the fatality rate can reach up to 90%. No licensed medicine is available. In this review, development of therapeutics for treatment of Ebola virus infection and EVD will be discussed.

Keywords: Antibody; Ebola virus; Ebola virus disease; Small-molecule compounds; Therapeutics; Treatment.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Antiviral Agents / pharmacology
Antiviral Agents / therapeutic use*
Ebola Vaccines / therapeutic use
Ebolavirus / drug effects
Ebolavirus / genetics
Hemorrhagic Fever, Ebola / drug therapy*
Hemorrhagic Fever, Ebola / prevention & control
Hemorrhagic Fever, Ebola / virology
Humans
RNA, Viral / biosynthesis
RNA, Viral / drug effects
RNA, Viral / genetics
Virus Internalization / drug effects

Substances

Antiviral Agents
Ebola Vaccines
RNA, Viral